Uvic Steratics

Seoul, South Korea Founded: 2018 • Age: 8 yrs
Anti-cancer drugs are developed via Proteolysis Targeting Chimera technology.
Annual revenue - Latest available
Total funding $17.6M 1 rounds
Employees - Tracked headcount
Investors 6 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Uvic Steratics

Uvic Steratics is a company based in Seoul (South Korea) founded in 2018. Uvic Steratics has raised $17.6 million across 1 funding round from investors including Korean Development Bank, Atinum Investment and Solidus Investment. Uvic Steratics operates in a competitive market with competitors including Accutar Biotechnology, Plexium, Photys Therapeutics, Lycia Therapeutics and Outruntx, among others.

  • Headquarter Seoul, South Korea
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Ubic Therapeutics Co., Ltd.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $17.6 M (USD)

    in 1 rounds

  • Latest Funding Round
    $17.6 M (USD), Series B

    Dec 24, 2024

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Uvic Steratics

Uvic Steratics has successfully raised a total of $17.6M through 1 strategic funding round. The most recent funding activity was a Series B round of $17.6 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Uvic Steratics

Uvic Steratics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Korean Development Bank, Atinum Investment and Solidus Investment.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Locked Locked Locked
A global venture platform focused on biotech and healthcare startups is operated.
Locked Locked Locked
VC firm investing in geographies such as South Korea
Locked Locked Locked
Premium access

Investor details for Uvic Steratics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Uvic Steratics

Investments
Premium access

Investment portfolio details for Uvic Steratics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Uvic Steratics

Premium access

Detailed financials for Uvic Steratics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Uvic Steratics Comparisons

Uvic Steratics Primary company
Description
Anti-cancer drugs are developed via Proteolysis Targeting Ch...
Location
Seoul, South Korea
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Uvic Steratics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Uvic Steratics

Uvic Steratics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Accutar Biotechnology, Plexium, Photys Therapeutics, Lycia Therapeutics and Outruntx, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
AI-assisted tools for drug discovery are developed.
Locked Locked Locked
Integrated chemistry service provider
Locked Locked Locked
Protein-based small molecules are developed to treat human diseases.
Locked Locked Locked
Protein degradation drugs are developed for cancer and autoimmune diseases.
Locked Locked Locked
Developer of therapeutics for cancer treatment
Premium access

Detailed competitors of Uvic Steratics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Uvic Steratics

Premium access

Complete news archive for Uvic Steratics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Uvic Steratics

Uvic Steratics was founded in 2018 and raised its 1st funding round 6 years after it was founded.

Uvic Steratics is headquartered in Seoul, South Korea.

Servo Optical is the current CEO of Uvic Steratics.

Uvic Steratics is a funded company, having raised a total of $17.6M across 1 funding round to date.

Founded in 2018 and based in Seoul, South Korea, Uvic Steratics operates in the biotechnology sector. Anti-cancer drugs are developed using an inhibitor technology that targets disease-related proteins for degradation. This approach involves binding the proteins near E3 ligases to activate the cellular proteolysis system, aiming for therapeutic effects through protein breakdown. Operations focus on advancing this chimera-based method for oncology applications.

Uvic Steratics's top competitors include Plexium, Photys Therapeutics and Accutar Biotechnology.

Uvic Steratics has 6 investors. Key investors include Korean Development Bank, Atinum Investment, Solidus Investment, Shinyoung Asset Management, and Mint Venture Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available